Infused therapy and survival in older patients diagnosed with metastatic breast cancer who received trastuzumab. - Wikidata - awgldk - TriplyDB

Infused therapy and survival in older patients diagnosed with metastatic breast cancer who received trastuzumab.

Infused therapy and survival in older patients diagnosed with metastatic breast cancer who received trastuzumab.

http://www.wikidata.org/entity/Q35540696

about

Estimating the Population Benefits and Costs of Rituximab Therapy in the United States from 1998 to 2013 Using Real-World Data Treatment patterns and clinical outcomes in elderly patients with HER2-positive metastatic breast cancer from the registHER observational study.Racial disparities in all-cause mortality among younger commercially insured women with incident metastatic breast cancer.Racial differences in outcomes for patients with metastatic breast cancer by disease subtype.Treatment patterns among elderly patients with stage IV breast cancer treated with HER-2-targeted therapy.Treatment Patterns and Outcomes in Elderly Patients with Metastatic Breast Cancer: A Multicenter Retrospective Study.Variation in guideline-concordant care for elderly patients with metastatic breast cancer in the United States.

P2860

Q31036587-A9733341-6392-4349-BF03-935979CBF310 Q36227614-5AD8719B-2922-4C80-9EE7-A89318E8FC5F Q39656542-A628F48C-538C-4F2D-947A-23399C03E89A Q40892038-161A61B6-1D97-4966-9584-85F53CA46506 Q44806586-1C6CD6B9-55BC-48CF-A5F4-190ADD4AB426 Q47110699-D8A4EEA3-88BA-4EFF-A8FE-002C11F2CE4D Q50053475-9300F71C-3A7E-4AF3-826B-49B766DDF6B3

P2860

Infused therapy and survival in older patients diagnosed with metastatic breast cancer who received trastuzumab.

http://www.wikidata.org/entity/Q35540696

description

2011 nî lūn-bûn

@nan

2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Infused therapy and survival i ...... ncer who received trastuzumab.

@ast

Infused therapy and survival i ...... ncer who received trastuzumab.

@en

type

label

Infused therapy and survival i ...... ncer who received trastuzumab.

@ast

Infused therapy and survival i ...... ncer who received trastuzumab.

@en

prefLabel

Infused therapy and survival i ...... ncer who received trastuzumab.

@ast

Infused therapy and survival i ...... ncer who received trastuzumab.

@en

P1433

Q35540696-5DA1DA4F-B321-4DF7-A2B8-C2E2CBCD9B02

P1476

Q35540696-9E059C4F-E126-4EE9-A09F-CAB440D26363

P2093

Q35540696-1446AAD2-439D-45AC-B44F-0063F7547334

Q35540696-20A156E6-AFE4-49B4-AFA0-0424C120C623

Q35540696-9B9EE031-94AE-4A14-AE6F-54A9BA5DF4CC

Q35540696-C532D5D5-8066-4AAA-ADC0-DB625CE9DF1A

Q35540696-C66DE266-B04D-4606-90C7-1B0CC264CAAB

Q35540696-EF32D6DC-19D7-4877-9ECB-EAD83EC19835

P2860

Q35540696-06F50F76-6820-4F1D-9171-A2A337189FCE

Q35540696-0E20FA48-EFBE-4670-9766-DE06432A40AA

Q35540696-1B7E3201-06BE-41DD-A2E8-C7A8EDF6A9DE

Q35540696-1F1C33D5-C6A6-4C6C-9E2F-7F98ED0C47CD

Q35540696-2AE1D5E0-84B2-45FA-B5C9-EB920E7DC137

Q35540696-347D173A-D66E-4B46-8D7C-09F1378ED0F3

Q35540696-35FB5817-B4F0-48D4-BB5D-240893A331A2

Q35540696-50287945-A9F7-4EEF-B37A-15F2A258F861

Q35540696-56A7E464-C5C4-4B68-908A-2791CD73C8D7

Q35540696-62D36637-3C5D-4AB4-8EC8-EA4EF53ED890

P304

Q35540696-39727D44-E6B5-4CD2-877E-E349465EA422

P31

Q35540696-D6E81A36-F44A-48F0-ADD4-062F6C14EC9B

P356

Q35540696-8DC6758A-32EC-4CAC-A133-613406F7F7BC

P433

Q35540696-D95DB0CF-43A5-4A79-B285-DFC9268F25E7

P478

Q35540696-839A8C99-CE69-491A-9313-B2B76CD2F0FE

P577

Q35540696-63A67BE7-84E4-4C5C-819A-2867AE75D717

P5875

Q35540696-A5801A07-AFED-4340-B02A-C43F0746F778

P698

Q35540696-175A3293-CF67-4D65-A346-D1BBA193FBEA

P932

Q35540696-09369716-E1EC-4529-8699-D39889E8A0E5

P356

07357907.2011.616251

P1433

Cancer Investigation

P1476

Infused therapy and survival i ...... ncer who received trastuzumab.

@en

P2093

Deepa Lalla

http://www.w3.org/2001/XMLSchema#string

Justin F Doan

http://www.w3.org/2001/XMLSchema#string

Mark D Danese

http://www.w3.org/2001/XMLSchema#string

Melissa G Brammer

http://www.w3.org/2001/XMLSchema#string

Robert I Griffiths

http://www.w3.org/2001/XMLSchema#string

Robert J Herbert

http://www.w3.org/2001/XMLSchema#string

P2860

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Trastuzumab--mechanism of action and use in clinical practice

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

The utility of Medicare claims data for measuring cancer stage.

Development of a comorbidity index using physician claims data.

Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population.

P304

573-584

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/07357907.2011.616251

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P577

2011-09-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51653716

http://www.w3.org/2001/XMLSchema#string

P698

21929325

http://www.w3.org/2001/XMLSchema#string

P932

3212922

http://www.w3.org/2001/XMLSchema#string